<DOC>
	<DOCNO>NCT01998906</DOCNO>
	<brief_summary>This study ass efficacy safety add Herceptin paclitaxel-containing regimen follow cyclophosphamide/methotrexate/fluorouracil ( CMF ) chemotherapy woman locally advance breast cancer HER2/c-erbB-2 gene amplification . In parallel observational study patient HER2-negative disease receive chemotherapy without Herceptin .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Combination Chemotherapy Women With Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>female patient , &gt; =18 year age , locally advanced breast cancer . previous therapy invasive malignancy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>